Cargando…
Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells
BACKGROUND: The molecular chaperone, heat shock protein 90 (Hsp90) has been shown to be overexpressed in a number of cancers, including prostate cancer, making it an important target for drug discovery. Unfortunately, results with N-terminal inhibitors from initial clinical trials have been disappoi...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3240935/ https://www.ncbi.nlm.nih.gov/pubmed/22039910 http://dx.doi.org/10.1186/1471-2407-11-468 |
_version_ | 1782219487585501184 |
---|---|
author | Eskew, Jeffery D Sadikot, Takrima Morales, Pedro Duren, Alicia Dunwiddie, Irene Swink, Megan Zhang, Xiaoying Hembruff, Stacey Donnelly, Alison Rajewski, Roger A Blagg, Brian SJ Manjarrez, Jacob R Matts, Robert L Holzbeierlein, Jeffrey M Vielhauer, George A |
author_facet | Eskew, Jeffery D Sadikot, Takrima Morales, Pedro Duren, Alicia Dunwiddie, Irene Swink, Megan Zhang, Xiaoying Hembruff, Stacey Donnelly, Alison Rajewski, Roger A Blagg, Brian SJ Manjarrez, Jacob R Matts, Robert L Holzbeierlein, Jeffrey M Vielhauer, George A |
author_sort | Eskew, Jeffery D |
collection | PubMed |
description | BACKGROUND: The molecular chaperone, heat shock protein 90 (Hsp90) has been shown to be overexpressed in a number of cancers, including prostate cancer, making it an important target for drug discovery. Unfortunately, results with N-terminal inhibitors from initial clinical trials have been disappointing, as toxicity and resistance resulting from induction of the heat shock response (HSR) has led to both scheduling and administration concerns. Therefore, Hsp90 inhibitors that do not induce the heat shock response represent a promising new direction for the treatment of prostate cancer. Herein, the development of a C-terminal Hsp90 inhibitor, KU174, is described, which demonstrates anti-cancer activity in prostate cancer cells in the absence of a HSR and describe a novel approach to characterize Hsp90 inhibition in cancer cells. METHODS: PC3-MM2 and LNCaP-LN3 cells were used in both direct and indirect in vitro Hsp90 inhibition assays (DARTS, Surface Plasmon Resonance, co-immunoprecipitation, luciferase, Western blot, anti-proliferative, cytotoxicity and size exclusion chromatography) to characterize the effects of KU174 in prostate cancer cells. Pilot in vivo efficacy studies were also conducted with KU174 in PC3-MM2 xenograft studies. RESULTS: KU174 exhibits robust anti-proliferative and cytotoxic activity along with client protein degradation and disruption of Hsp90 native complexes without induction of a HSR. Furthermore, KU174 demonstrates direct binding to the Hsp90 protein and Hsp90 complexes in cancer cells. In addition, in pilot in-vivo proof-of-concept studies KU174 demonstrates efficacy at 75 mg/kg in a PC3-MM2 rat tumor model. CONCLUSIONS: Overall, these findings suggest C-terminal Hsp90 inhibitors have potential as therapeutic agents for the treatment of prostate cancer. |
format | Online Article Text |
id | pubmed-3240935 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-32409352011-12-17 Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells Eskew, Jeffery D Sadikot, Takrima Morales, Pedro Duren, Alicia Dunwiddie, Irene Swink, Megan Zhang, Xiaoying Hembruff, Stacey Donnelly, Alison Rajewski, Roger A Blagg, Brian SJ Manjarrez, Jacob R Matts, Robert L Holzbeierlein, Jeffrey M Vielhauer, George A BMC Cancer Research Article BACKGROUND: The molecular chaperone, heat shock protein 90 (Hsp90) has been shown to be overexpressed in a number of cancers, including prostate cancer, making it an important target for drug discovery. Unfortunately, results with N-terminal inhibitors from initial clinical trials have been disappointing, as toxicity and resistance resulting from induction of the heat shock response (HSR) has led to both scheduling and administration concerns. Therefore, Hsp90 inhibitors that do not induce the heat shock response represent a promising new direction for the treatment of prostate cancer. Herein, the development of a C-terminal Hsp90 inhibitor, KU174, is described, which demonstrates anti-cancer activity in prostate cancer cells in the absence of a HSR and describe a novel approach to characterize Hsp90 inhibition in cancer cells. METHODS: PC3-MM2 and LNCaP-LN3 cells were used in both direct and indirect in vitro Hsp90 inhibition assays (DARTS, Surface Plasmon Resonance, co-immunoprecipitation, luciferase, Western blot, anti-proliferative, cytotoxicity and size exclusion chromatography) to characterize the effects of KU174 in prostate cancer cells. Pilot in vivo efficacy studies were also conducted with KU174 in PC3-MM2 xenograft studies. RESULTS: KU174 exhibits robust anti-proliferative and cytotoxic activity along with client protein degradation and disruption of Hsp90 native complexes without induction of a HSR. Furthermore, KU174 demonstrates direct binding to the Hsp90 protein and Hsp90 complexes in cancer cells. In addition, in pilot in-vivo proof-of-concept studies KU174 demonstrates efficacy at 75 mg/kg in a PC3-MM2 rat tumor model. CONCLUSIONS: Overall, these findings suggest C-terminal Hsp90 inhibitors have potential as therapeutic agents for the treatment of prostate cancer. BioMed Central 2011-10-31 /pmc/articles/PMC3240935/ /pubmed/22039910 http://dx.doi.org/10.1186/1471-2407-11-468 Text en Copyright ©2011 Eskew et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Eskew, Jeffery D Sadikot, Takrima Morales, Pedro Duren, Alicia Dunwiddie, Irene Swink, Megan Zhang, Xiaoying Hembruff, Stacey Donnelly, Alison Rajewski, Roger A Blagg, Brian SJ Manjarrez, Jacob R Matts, Robert L Holzbeierlein, Jeffrey M Vielhauer, George A Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells |
title | Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells |
title_full | Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells |
title_fullStr | Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells |
title_full_unstemmed | Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells |
title_short | Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells |
title_sort | development and characterization of a novel c-terminal inhibitor of hsp90 in androgen dependent and independent prostate cancer cells |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3240935/ https://www.ncbi.nlm.nih.gov/pubmed/22039910 http://dx.doi.org/10.1186/1471-2407-11-468 |
work_keys_str_mv | AT eskewjefferyd developmentandcharacterizationofanovelcterminalinhibitorofhsp90inandrogendependentandindependentprostatecancercells AT sadikottakrima developmentandcharacterizationofanovelcterminalinhibitorofhsp90inandrogendependentandindependentprostatecancercells AT moralespedro developmentandcharacterizationofanovelcterminalinhibitorofhsp90inandrogendependentandindependentprostatecancercells AT durenalicia developmentandcharacterizationofanovelcterminalinhibitorofhsp90inandrogendependentandindependentprostatecancercells AT dunwiddieirene developmentandcharacterizationofanovelcterminalinhibitorofhsp90inandrogendependentandindependentprostatecancercells AT swinkmegan developmentandcharacterizationofanovelcterminalinhibitorofhsp90inandrogendependentandindependentprostatecancercells AT zhangxiaoying developmentandcharacterizationofanovelcterminalinhibitorofhsp90inandrogendependentandindependentprostatecancercells AT hembruffstacey developmentandcharacterizationofanovelcterminalinhibitorofhsp90inandrogendependentandindependentprostatecancercells AT donnellyalison developmentandcharacterizationofanovelcterminalinhibitorofhsp90inandrogendependentandindependentprostatecancercells AT rajewskirogera developmentandcharacterizationofanovelcterminalinhibitorofhsp90inandrogendependentandindependentprostatecancercells AT blaggbriansj developmentandcharacterizationofanovelcterminalinhibitorofhsp90inandrogendependentandindependentprostatecancercells AT manjarrezjacobr developmentandcharacterizationofanovelcterminalinhibitorofhsp90inandrogendependentandindependentprostatecancercells AT mattsrobertl developmentandcharacterizationofanovelcterminalinhibitorofhsp90inandrogendependentandindependentprostatecancercells AT holzbeierleinjeffreym developmentandcharacterizationofanovelcterminalinhibitorofhsp90inandrogendependentandindependentprostatecancercells AT vielhauergeorgea developmentandcharacterizationofanovelcterminalinhibitorofhsp90inandrogendependentandindependentprostatecancercells |